These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 31841594)

  • 1. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
    Roboz GJ; DiNardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP; Mannis GN; Pollyea DA; Stein AS; Uy GL; Watts JM; Fathi AT; Kantarjian HM; Tallman MS; Choe S; Dai D; Fan B; Wang H; Zhang V; Yen KE; Kapsalis SM; Hickman D; Liu H; Agresta SV; Wu B; Attar EC; Stone RM
    Blood; 2020 Feb; 135(7):463-471. PubMed ID: 31841594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
    J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
    DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML; Sallman DA; Hossain M; Marchione DM; Bai X; Patel PA; Kapsalis SM; Garcia-Manero G; Fathi AT
    Blood Adv; 2024 Aug; 8(15):4209-4220. PubMed ID: 38640348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
    Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
    Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
    de Botton S; Fenaux P; Yee K; Récher C; Wei AH; Montesinos P; Taussig DC; Pigneux A; Braun T; Curti A; Grove C; Jonas BA; Khwaja A; Legrand O; Peterlin P; Arnan M; Blum W; Cilloni D; Hiwase DK; Jurcic JG; Krauter J; Thomas X; Watts JM; Yang J; Polyanskaya O; Brevard J; Sweeney J; Barrett E; Cortes J
    Blood Adv; 2023 Jul; 7(13):3117-3127. PubMed ID: 36724515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivosidenib and Azacitidine in
    Montesinos P; Recher C; Vives S; Zarzycka E; Wang J; Bertani G; Heuser M; Calado RT; Schuh AC; Yeh SP; Daigle SR; Hui J; Pandya SS; Gianolio DA; de Botton S; Döhner H
    N Engl J Med; 2022 Apr; 386(16):1519-1531. PubMed ID: 35443108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
    Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
    Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
    Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA
    Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
    Choe S; Wang H; DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Watts JM; Pollyea DA; Fathi AT; Tallman MS; Kantarjian HM; Stone RM; Quek L; Konteatis Z; Dang L; Nicolay B; Nejad P; Liu G; Zhang V; Liu H; Goldwasser M; Liu W; Marks K; Bowden C; Biller SA; Attar EC; Wu B
    Blood Adv; 2020 May; 4(9):1894-1905. PubMed ID: 32380538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular remission and response patterns in patients with mutant-
    Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
    Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
    Donker ML; Ossenkoppele GJ
    Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.